Pertuzumab is a monoclonal antibody used in the treatment of breast cancer. It is used in combination with other drugs, such as trastuzumab and chemotherapy, to treat HER2-positive breast cancer. Pertuzumab works by blocking the HER2 receptor, which is found on the surface of some cancer cells. This prevents the cancer cells from receiving signals that promote their growth and survival. Pertuzumab is approved for use in combination with trastuzumab and chemotherapy for the treatment of HER2-positive metastatic breast cancer. It is also approved for use in combination with trastuzumab and docetaxel for the treatment of HER2-positive early-stage breast cancer. Companies in the Pertuzumab market include Roche, Merck, Pfizer, and AstraZeneca. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
